A Phase I, Open-Label, Dose-Escalation, First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics, and Pharmacodynamics of GSK923295 in Subjects With Refractory Cancers.

Trial Profile

A Phase I, Open-Label, Dose-Escalation, First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics, and Pharmacodynamics of GSK923295 in Subjects With Refractory Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs GSK 923295 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 08 Apr 2011 Planned End Date changed to 1 May 2012, according to ClinicalTrials.gov.
    • 08 Apr 2011 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov.
    • 31 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top